Cervagem
Last Updated on eMC 17-Jan-2014 View document | SANOFI Contact details
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 17-Jan-2014 and displayed until Current
Reasons for adding or updating:
- Change to section 4.8 - Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Date of revision of text on the SPC: 09-Jan-2014
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Section 4.8 updated to include the new PV Legislation wording on adverse effect reportingUpdated on 20-Jun-2012 and displayed until 17-Jan-2014
Reasons for adding or updating:
- Change to section 1 -Name of the Medicinal product
Date of revision of text on the SPC: 09-Feb-2012
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
This SPC has been reloaded under 'Cervagem' rather than 'Gemeprost'Updated on 20-Feb-2012 and displayed until 20-Jun-2012
Reasons for adding or updating:
- Change to section 10 date of revision of the text
- Change to section 1 -Name of the Medicinal product
Date of revision of text on the SPC: 09-Feb-2012
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Section 1 updated with the addition of an alternative name of the medicinal product 'Cervagem 1mg Pessary'. The existing product name has been aligned with the QRD template.Updated on 17-Sep-2007 and displayed until 20-Feb-2012
Reasons for adding or updating:
- Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC: 01-Oct-2006
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Section 7 (Marketing Authorisation Holder): change to MA Holder's addressUpdated on 17-Aug-2006 and displayed until 17-Sep-2007
Reasons for adding or updating:
- Change to section 10 (date of (partial) revision of the text
Date of revision of text on the SPC: 01-Sep-2005
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Change to date in section 10Updated on 14-Mar-2006 and displayed until 17-Aug-2006
Reasons for adding or updating:
- Change to section 7 - Marketing Authorisation Holder
- Change to section 8 - MA number
Updated on 14-Jan-2002 and displayed until 14-Mar-2006
Reasons for adding or updating:
- Change to section 4.3 - Contra-indications
Updated on 16-Jul-2001 and displayed until 14-Jan-2002
Reasons for adding or updating:
- Transferred from eMC version 1
Updated on 08-Dec-2000 and displayed until 16-Jul-2001
Reasons for adding or updating:
- No reasons supplied
SANOFI
1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
+44 (0)1483 535 432
+44 (0)1483 505 515
+44 (0)845 372 7101
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue